I'm certainly no expert, so FWIW as add on comment
Post# of 11802
GenPrecis is what will differentiate DECN in the market and staying on target with that is key. Any other ways to get some revenue in the interim are well received and should be prioritized accordingly - GenChoice, PetSure, GenUltimate, GenSure - whichever. The company will need to determine where the sweet spot is for revenue generation from resources available.
Wait a couple days to see what the company provides and we'll see if things progress on the J&J case heading into the end of the year.